Borissova Anya, Rucker James J
Centre for Neuroimaging Sciences, King's College London, UK.
Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
BJPsych Bull. 2024 Feb;48(1):38-44. doi: 10.1192/bjb.2023.25.
Psilocybin is a classic psychedelic drug that has attracted increasing research interest over the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (TRD) demonstrated encouraging signs of basic safety, further confirmed by a large study in groups of healthy volunteers. The first international multi-centre randomised controlled trial was published in 2022, with signs of efficacy for the 25 mg dose condition in people with TRD when compared with an active placebo. Phase 3 trials in TRD are scheduled to start in 2023. Early evidence suggests that single doses of psilocybin given with psychological support induce rapid improvement in depressive symptoms that endure for some weeks. We therefore provide a timely update to psychiatrists on what psilocybin therapy is, what it is not, and the current state of the evidence-base.
裸盖菇素是一种经典的致幻药物，在过去十年中，作为治疗情绪、焦虑及相关病症的一种可能疗法，它吸引了越来越多的研究关注。裸盖菇素与心理支持相结合用于治疗重度抑郁症和难治性抑郁症（TRD）的初步2期临床试验显示出令人鼓舞的基本安全性迹象，一项针对健康志愿者群体的大型研究进一步证实了这一点。首个国际多中心随机对照试验于2022年发表，与活性安慰剂相比，25毫克剂量条件下的裸盖菇素对TRD患者显示出疗效迹象。TRD的3期试验计划于2023年开始。早期证据表明，在心理支持下给予单剂量裸盖菇素可使抑郁症状迅速改善，并持续数周。因此，我们及时向精神科医生介绍裸盖菇素疗法是什么、不是什么以及当前证据基础的状况。
